Type
miREIA – miRNA enzyme immunoassay
Applications
Serum, Plasma-EDTA, Urine, Whole blood, Cell culture lysates, PBMC
Sample Requirements
10 µl/well
Shipping
At ambient temperature. Upon receipt, store the product at the temperature recommended below.
Storage/Expiration
Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).
Calibration Range
6.25 – 0.195 amol/μl
Limit of Detection
0.065 amol/μl
Intra-assay (Within-Run)
n = 8,
CV = 5.2%
Inter-assay (Run-to-Run)
n = 5,
CV = 5.7%
Spiking Recovery
97.1%
Dilution Linearity
96.5%
Features
- It is intended for research use only
- The total assay time is less than 2.5 hours
- The kit measures hsa-piR-5937 isolated from human blood
- Assay format is 96 wells
- Standard is synthetic piRNA-based
- Components of the kit are provided ready to use, concentrated or dried
Research topic
Oncology
Summary
PIWI-Interacting RNAs (piRNAs) are small non-coding RNA molecules of approximately 24–32 nucleotides in length that often bind to members of the piwi protein family to play regulatory roles. Recently, emerging evidence suggests that in addition to the mammalian germline, piRNAs are also expressed in a tissue-specific manner in a variety of human tissues and modulate key signaling pathways at the transcriptional or post-transcriptional level. piRNAs have been shown to participate in the epigenetic regulation of cancer and other diseases and are key elements of cellular homeostasis. Furthermore, they play an important role in tumor formation, proliferation, and migration of the cells. Similar to miRNAs, piRNAs posttranscriptional regulation occurs in the cytoplasm. Numerous studies have suggested that piRNA and PIWI proteins, which are abnormally expressed in various cancers, may serve as novel promising biomarkers and therapeutic targets for tumor diagnostics and treatment.
Based on the levels of piR-5937 and piR-28876, it was possible to differentiate between cancer patients and healthy donors with high sensitivity and specificity. Moreover, both piRNAs exhibited satisfactory diagnostic performance also in patients with stage I disease and enabled detection of colon cancer with higher sensitivity than currently used biomarkers CEA and CA19-9.
